Benitec Biopharma Debt to Equity Ratio 2014-2022 | BNTC
Current and historical debt to equity ratio values for Benitec Biopharma (BNTC) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Benitec Biopharma debt/equity for the three months ending September 30, 2022 was 0.03.
| Benitec Biopharma Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-09-30 |
$0.00B |
$0.02B |
0.24 |
| 2022-06-30 |
$0.00B |
$0.00B |
1.07 |
| 2022-03-31 |
$0.00B |
$0.01B |
0.34 |
| 2021-12-31 |
$0.00B |
$0.01B |
0.29 |
| 2021-09-30 |
$0.00B |
$0.02B |
0.15 |
| 2021-06-30 |
$0.00B |
$0.02B |
0.07 |
| 2021-03-31 |
$0.00B |
$0.01B |
0.23 |
| 2020-12-31 |
$0.00B |
$0.02B |
0.06 |
| 2020-09-30 |
$0.00B |
$0.01B |
0.15 |
| 2020-06-30 |
$0.00B |
$0.01B |
0.13 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.00B |
$0.02B |
0.07 |
| 2019-09-30 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.00B |
$0.02B |
0.09 |
| 2016-09-30 |
$0.00B |
$0.02B |
0.05 |
| 2016-06-30 |
$0.00B |
$0.01B |
0.06 |
| 2016-03-31 |
$0.00B |
$0.02B |
0.09 |
| 2015-12-31 |
$0.00B |
$0.02B |
0.04 |
| 2015-06-30 |
$0.00B |
$0.02B |
0.07 |
| 2014-12-31 |
$0.00B |
$0.03B |
0.02 |
| 2014-06-30 |
$0.00B |
$0.03B |
0.03 |
| 2013-06-30 |
$0.00B |
$0.00B |
1.75 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
